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Abstract
Individuals with spinal muscular atrophy (SMA) type 3 are able to walk but they have weak-
ness, gait impairments and fatigue. Our primary study objective was to examine longitudinal
changes in the six-minute walk test (6MWT) and to evaluate whether age and SMA type 3
subtype are associated with decline in ambulatory function. Data from three prospective nat-
ural history studies were used. Seventy-three participants who performed the 6MWT more
than once, at least 6 months apart, were included; follow-up ranged from 0.5–9 years. Only
data from patients who completed the 6MWT were included. The mean age of the partici-
pants was 13.5 years (range 2.6–49.1), with 52 having disease onset before age 3 years
(type 3A). At baseline, type 3A participants walked a shorter distance on average (257.1 m)
than type 3B participants (390.2 m) (difference = 133.1 m, 95% confidence interval [CI]
71.8–194.3, p < 0.001). Distance walked was weakly associated with age (r = 0.25, p =
0.04). Linear mixed effects models were used to estimate the mean annual rate of change.
The overall mean rate of change was -7.8 m/year (95% CI -13.6 –-2.0, p = 0.009) and this
did not differ by subtype (type 3A: -8.5 m/year, type 3B: -6.6 m/year, p = 0.78), but it did differ
by age group (< 6: 9.8 m/year; 6–10: -7.9 m/year; 11–19: -20.8 m/year; 20: -9.7 m/year;
p = 0.005). Our results showed an overall decline on the 6MWT over time, but different tra-
jectories were observed depending on age. Young ambulant SMA patients gain function but
in adolescence, patients lose function. Future clinical trials in ambulant SMA patients should
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Introduction
Spinal muscular atrophy (SMA) is a genetically determined neuromuscular disorder that
affects motor neurons and their associated motor units, causing muscle atrophy and weakness.
The most common cause of the SMA phenotype is a homozygous deletion of the Survival
Motor Neuron (SMN1) gene located on chromosome 5q13. [1]Individuals with the mildest
phenotype, SMA type 3, are able to walk independently, [2] but their residual weakness causes
gait impairments and fatigue, [3–5] and ultimately can result in loss of ambulation. [2]
In the chronic forms of SMA, which include types 2 and 3, gross motor function worsens
slowly over time with minimal changes observed in one year [6] and small changes over 4
years. [7] However, while SMA is thought to be a largely stable disorder, recent studies have
highlighted different rates of progression based on age and function. [8–10] In non-ambulant
patients, gross motor function improves until about age 5 years, and then worsens until age 15
years, followed by a relatively stable plateau phase in late adolescence and adulthood. [8] While
ambulant patients have a similar trajectory of progression to that of non-ambulant patients
when assessed using functional scales, [8] it has been suggested that a more specific assessment
may be necessary to identify changes in ambulatory function. [11]
Assessments of walking ability are clinically relevant in this population. The six-minute
walk test (6MWT) is a valid and reliable functional outcome measure in SMA. [12] Longitudi-
nal studies have demonstrated minimal changes in the 6MWT over a 12-month period in a
small, mixed cohort of children and adults. [13] While the majority of individuals had minimal
changes in this study, greater changes were seen in children between the ages of 6 and 16.
The purpose of this study was to examine longitudinal changes in the 6MWT beyond one
year in a larger cohort of SMA patients and to explore if changes in ambulatory function are
associated with age or SMA subtype.
Materials and methods
Data from three on-going prospective natural history studies in the US, Italy and UK were
used in this investigation. Patients of any age or SMA type diagnosed with 5q SMA disease
were offered participation. Exclusion criteria included patients with symptom onset of SMA
after age 19 years and presence of unstable medical conditions. To reduce selection bias, all
patients seen in neuromuscular clinics who fulfilled eligibility criteria were enrolled. Partici-
pants were scheduled to be evaluated every 6 months for up to 9 years. Only ambulatory par-
ticipants who performed the 6MWT were included in the data analysis for this report. Those
ambulatory participants with clinical symptoms before age 3 years were termed Type 3A and
the others with the onset of clinical symptoms after age 3 years were termed Type 3B. [14] All
three network specific natural history studies had local ethical approvals in place permitting
the pilot of functional scales (SMA REACH UK: National Research Ethics Committee (REC)
London Bromley, Health Research Authority REC reference 13/LO/1748; PNCR USA Institu-
tional Review Boards (IRB) and Numbers: Columbia University Medical Center Human
Research Protection Office IRB reference AAAE8252, The Children’s Hospital of Philadelphia
IRB reference 10–007816, Boston Children’s Hospital Office of Clinical Investigations IRB ref-
erence 05-02-028, Stanford University Research Compliance Office IRB reference 31140). The
Italian ethical requirements for natural history studies mean that the Italian SMA Network
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was not provided with an IRB number. All participants had given their explicit written
informed consent to participate in the network specific natural history studies.
Motor function assessments were performed at every visit and determined based on func-
tional ability in these natural history studies. The Children’s Hospital of Philadelphia Infant
Test of Neuromuscular Disorders was used to evaluate SMA type 1 infants and non-sitters [15]
whereas the Hammersmith Functional Motor Scale Expanded was used for those with SMA
types 2 and 3 [16]. For participants who were able to walk without support for at least 10
meters, the Six-Minute Walk Test (6MWT) was used to assess ambulatory function. Since the
focus of this study is ambulatory function, only 6MWT data were included in the analysis.
Other details about the broader natural history study and outcome measures used are
described in previous reports. [6, 7]
Six-minute walk test (6MWT)
The 6MWT measures the maximum distance a person can walk in 6 minutes over a 25-meter
linear course. It has been shown to be a valid and reliable assessment of exercise capacity and
functional walking ability in SMA patients. [12] Distance walked over the entire 6 minute time
period, distance covered each minute, and the time to complete each 25-meter interval were
recorded. Successful completion was determined by the evaluator if the participant walked
along the course without support or assistance for 6 minutes. Standing rests were permitted as
often as needed but sitting was not permitted. Data were collected according to previously
published guidelines [3] and identically across the three networks. Training was performed
independently in US and European networks. As part of the activity of each network, evalua-
tors used a common procedure manual [3] and were trained at in-person meetings.
Statistical methods
Mean values of the 6MWT distance walked at baseline were compared between SMA subtypes
3A and 3B and between male and female participants using t-tests. Pearson’s correlation coeffi-
cient was used to quantify the association between age and 6MWT distance walked at baseline.
Linear mixed effects models were used to estimate the mean annual rate of change (slope) for
the whole group as well as by SMA subtype and age group (< 6, 6–10, 11–19, 20 years). Age
groups were chosen to classify younger, intermediate, adolescent, and adult participants and
are similar to those used in previous reports. [8] The model for estimating the overall mean
slope included year of follow-up (continuous) with random intercept and slope coefficients.
To make inferences about mean slopes in subgroups, the above model was expanded by
including appropriate main effect and interaction terms in the model (e.g., age group and the
age group by year interaction). Pairwise comparisons of mean slopes among the four age
groups used a Bonferroni-corrected significance level of 0.05/6 = 0.0083.
Results
Seventy-three ambulatory participants (33 female) who performed the 6MWT successfully
more than once, at least 6 months apart, were included; follow-up ranged from 0.5 to 9 years.
The mean age of the participants was 13.5 years (range 2.6–49.1), with 52 (71%) having disease
onset before age 3 years (type 3A) and 21 (29%) having disease onset after age 3 years (type 3B)
(Table 1). Overall, there were slightly more male participants (54.8%); however, the milder
phenotype (type 3B) was predominantly male (85.7%).
At the initial visit, the 6MWT ranged between 38 and 604 meters (mean ± standard devia-
tion 295 ± 133 m); type 3B participants walked a longer distance on average (390 ± 144 m)
than type 3A participants (257 ± 107 m) (difference = 133 m, 95% CI 72–194, p< 0.001) and
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male participants walked a longer distance on average (325 ± 137 m) than female participants
(259 ± 121 m) (difference = 66 m, 95% CI 5–126, p = 0.03). Total distance walked was weakly
associated with age (r = 0.25, p = 0.04).
The mean rates of change in 6MWT distance, overall and by SMA subtype and age group,
are provided in Table 2. The overall mean rate of change was -7.8 m/year (p = 0.009) and this
did not differ by SMA subtype (type 3A: -8.5 m/year; type 3B: -6.6 m/year; p = 0.78) or gender
(male: -10.0 m/year; female: -5.9 m/year; p = 0.51), but it did differ by age group (< 6: 9.8 m/
year; 6–10: -7.9 m/year; 11–19: -20.8 m/year; 20: -9.7 m/year; p = 0.005 for the interaction
between age group and time (Fig 1). The most prominent age group differences in mean
annual rate of change were those between < 6 and 11–19 years (p = 0.0009) and between 6–10
and 11–19 years (p = 0.008) (Table 3). The individual trajectories by age group are shown in
Fig 2.
Discussion
Similar to non-ambulant patients, ambulant SMA individuals have different disease trajecto-
ries based on age. Ambulant SMA patients have improving walking ability until about age 6
years, a slowly declining phase until adolescence, then a steeper decline around puberty and
until age 20 years, after which there is another slowly declining phase through adulthood. The
age around puberty appeared to be the most vulnerable period in ambulant patients, as was
Table 2. Mean annual rate of change on the 6MWT, overall and by subgroup.
N Mean Annual Rate of Change 95% CI P-value
Overall 73 -7.8 (-13.6, -2.0) 0.009
SMA subtype
3A 52 -8.5 (-15.2, -1.7) 0.02
3B 21 -6.6 (-17.7, 4.4) 0.24
Age group
< 6 years 24 9.8 (-6.2, 25.9) 0.23
6–10 years 24 -7.9 (-15.7, -0.1) 0.05
11–19 years 10 -20.8 (-31.1, -10.6) < 0.0001
 20 years 15 -9.7 (-19.3, -0.1) 0.05
CI = Confidence interval
https://doi.org/10.1371/journal.pone.0199657.t002
Table 1. Baseline clinical characteristics for all participants by age and SMA subtype.
Variable Type 3A(n = 52) Type 3B(n = 21) Overall(n = 73)
Age (years) 7.9 (6.9) 27.3 (12.4) 13.5 (12.4)
Male (%) 42.3 85.7 54.8
Study (%)
PNCRN 36.5 42.9 38.4
Italian SMANetwork 23.1 57.1 32.9
SMA REACH UK 40.4 0 28.8
6MWT Total distance (m) 257.1 (107.3) 390.2 (144.0) 295.4 (132.6)
Values are mean (standard deviation) or % as indicated
PNCRN = Pediatric Neuromuscular Clinical Research Network
6MWT = Six-Minute Walk Test
https://doi.org/10.1371/journal.pone.0199657.t001
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also observed in our previous study using gross motor function scales. [8] Since hip and knee
contractures and scoliosis are rarely a problem for ambulant SMA patients, weight gain and
growth associated with puberty may contribute to progression in the setting of a limited neu-
romuscular system.
In this study, male participants walked farther than female participants on average. Our
findings are in contrast to reports suggesting there may be genetic modifiers that are beneficial
to female patients, particularly in the post-pubertal period. [17] These findings, however,
should be interpreted with caution: while our overall study sample was largely balanced with
respect to sex (56% male), nearly all of the type 3B patients (85.7%) were male. A greater repre-
sentation of male patients in the milder cohort could have contributed to the overall sex differ-
ences in distance walked on the 6MWT. Future studies should explore if the distribution of sex
differs according to phenotype among ambulatory SMA patients.
All clinical sites participating in this study are specialized neuromuscular centres in their
respective geographical regions. The vast majority of patients referred are enrolled in the natu-
ral history studies. Rarely, does a patient or family refuse participation. While this should
Fig 1. Mean annual rate of change in 6MWT distance and 95% confidence interval by age group.
https://doi.org/10.1371/journal.pone.0199657.g001
Table 3. Age group comparisons of mean annual rate of change on the 6MWT.
Comparison Difference in Mean Annual Rate of Change 95% CI P-value
< 6 vs. 6–10 years -17.8 (-34.1, -1.4) 0.03
< 6 vs. 11–19 years -30.7 (-48.6, -12.7) 0.0009
< 6 vs. 20 years -19.6 (-38.0, -1.1) 0.04
6–10 vs. 11–19 years -12.9 (-22.4, -3.4) 0.008
6–10 vs. 20 years -1.8 (-13.8, 10.2) 0.77
11–19 vs. 20 years 11.1 (-2.5, 24.7) 0.11
CI = Confidence interval
https://doi.org/10.1371/journal.pone.0199657.t003
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broadly represent the population at large, a selection bias secondary to the pattern of referrals
to individual centres cannot be excluded. Importantly, the SMA 3 patient cohort included in
this study is similar to those in previously reported natural history studies. [10, 14]
While patients with type 3B walked farther on the 6MWT on average at baseline, their
mean rate of progression did not differ significantly from that of type 3A patients in this study.
This is consistent with our previous observation using gross motor function scales where the
rate of progression did not differ in ambulant subtypes over 1 year. [8] However, since the type
3A patients walked less overall, they may be at greater risk for losing ambulation.
On average, ambulant adolescent patients lost nearly 21 meters per year on the 6MWT in
this study. While the precise impact of changes in the 6MWT on activities of daily living has
not been explored in SMA, similar changes have been associated with decreased daily activities
and participation in other neuromuscular disorders. [18] For clinical trials, stabilization of
6MWT distance in this population may therefore indicate an important therapeutic benefit.
None of the patients in our cohort lost ambulation. Further studies with longer follow up
may help to prospectively capture loss of ambulation and to identify possible prognostic indi-
cators of reaching this important endpoint. This would also help to identify if a number of fac-
tors such as changes in ankle range of motion, weight gain, progression of weakness or
Fig 2. Individual trajectories and average trajectory of 6MWT distance by age group.
https://doi.org/10.1371/journal.pone.0199657.g002
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prolonged immobilization from injury may be considered as possible risk factors for loss of
ambulation. This would permit proactive management and targeted intervention strategies.
While initially designed as an assessment of functional exercise capacity and responsiveness
to treatment in cardiopulmonary disease, [19], the 6MWT has been incorporated in the func-
tional evaluation of children with chronic pediatric conditions [20] and neuromuscular condi-
tions including Duchenne muscular dystrophy [18] and SMA. [5, 13] Furthermore, the
6MWT has been included as a primary and secondary endpoint in clinical trials with children
and adults with neuromuscular disease. [21–24]
With the availability of a disease modifying therapy [25] and additional emerging therapeu-
tic interventions in development or clinical trials, [26] the potential for a new treated SMA
phenotype is possible. [27] A need for objective and sensitive outcome measures targeting
ambulatory, higher functioning children and adults can be anticipated. The 6MWT is a practi-
cal, easily administered assessment that is incorporated into clinical practice and management
of SMA patients. Understanding the natural history of the disease and identifying disease tra-
jectories as measured by the 6MWT is essential to interpret responsiveness to treatment in
both a clinical and research settings.
Conclusions
The 6MWT provides a global assessment of functional mobility, fatigue, strength and ability to
walk. While overall walking ability slowly declined in the studied cohort over time, different
trajectories were observed on the 6MWT in children and adults depending on age. Similar to
non-ambulant SMA patients, young ambulant SMA patients gain function while in childhood,
whereas early adulthood patients lose function. To date, treatment trials have mainly focused
on infants and non-walkers. Future clinical trials will likely target the milder untreated ambu-
latory phenotypes. In these studies, the 6MWT should be considered as a possible important
outcome measure. For study design, considerations for different trajectories of disease pro-
gression based on age (e.g., eligibility criteria, stratification) should be included.
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